Ashling Wahner

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

Pamela T. Soliman, MD, MPH, discusses a phase 1 investigation of temsirolimus plus metformin in patients with recurrent endometrial cancer.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

The FDA has awarded full approval to frontline nivolumab plus ipilimumab for the treatment of adult patients with unresectable hepatocellular carcinoma.

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

An independent DSMB found MaaT033 to have a favorable safety profile in patients with hematologic malignancies undergoing allo-HSCT in the PHOEBUS trial.

Chandler Park, MD, FACP, discusses optimal clinical scenarios for the use of the 3 approved first-line treatment options for patients with bladder cancer.

The FDA has granted approval to nivolumab plus ipilimumab for the treatment of patients with dMMR/MSI-H metastatic colorectal cancer.

Induction R-DA-EDOCH/R-DHAP therapy yields high rates of CR, overall response, and MRD negativity in young patients with newly diagnosed, high-risk MCL.

The combination of VXM01 and avelumab was well tolerated and has the potential to generate clinically meaningful responses in recurrent glioblastoma.

Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Read a recap of the episodes of OncLive On Air that aired in March 2025.

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

Steven Devine, MD; Everett Meyer, MD, PhD; and Sophie Paczesny, MD, PhD, discuss their most highly anticipated presentations from the 2025 EBMT Meeting.

The investigational new drug application for the RDC SKB107 for the management of solid tumor bone metastases has been approved in China.

Olalekan O. Oluwole, MD, discusses research findings showing that patients with LBCL may not need prolonged hospital monitoring following axi-cel infusion.

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

Tsewang Tashi, MD, discusses the efficacy and tolerability of targeted therapies like avapritinib for patients with indolent systemic mastocytosis.

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

David M. Swoboda, MD, discusses data with quizartinib in FLT3-negative AML from the QUIWI trial and the rationale for the QuANTUM-Wild trial.

Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.

BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer.